Company Overview
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $6.39M (+181.5% YoY); net profit $-117.26M.
- Trailing 12 Months Year-on-year growth — revenue +181.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -22.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -22.26% |
| 1 Year: | 181.46% |
Stock Price Performance
| 1 Year: | -36.71% |
| 6 Months: | -7.06% |
| 3 Months: | +11.75% |
| 1 Month: | +25.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Death Cross7d ago
- RSI (14)61.69 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -22.3% CAGR over 5 years.
- Trading 76.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRRO Korro Bio, Inc. R2KR3KPHARMA | 11.98 | -1.21 | $176.41M | 0.00% | -119.97% | -97.69% | -22.26% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 24.24M | 4.71M | 7.26M | 8.52M | 11.25M | 9.95M | 4.65M | 9.42M | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | -5.06M | - | -5.92M | -7.02M | -1.25M | - | -5.66M | -6.20M | -5.42M | - | -20.20M | -17.48M | -24.99M | -23.26M | -21.27M | -20.27M | -20.09M | -18.41M | -19.15M | -21.45M | -24.12M | -23.29M | -25.02M | -27.20M | -19.24M | -20.44M | -20.11M |
| Net Income | -4.15M | -4.44M | -5.14M | -5.45M | -5.83M | -6.85M | -575.00K | -5.49M | -4.91M | -6.03M | -5.34M | -10.23M | -20.38M | -17.66M | -25.16M | -23.39M | -21.29M | -19.55M | -19.61M | -17.65M | -18.49M | -19.56M | -21.83M | -21.00M | -23.39M | -25.77M | -18.06M | -19.62M | -18.92M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.55 | -72.20 | -63.83 | -65.08 | -2.44 | -2.43 | -2.26 | -2.49 | -2.74 | -1.92 | -1.69 | -1.07 |
| R&D Expense | - | - | 3.55M | - | 3.45M | 3.92M | 5.22M | - | 6.67M | 8.76M | 10.15M | - | 15.11M | 17.40M | 15.66M | 13.78M | 13.27M | 11.71M | 14.69M | 13.13M | 14.01M | 13.57M | 17.14M | 15.96M | 19.74M | 21.03M | 13.82M | 12.95M | 13.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 28.95M | 36.98M | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Operating Income | -16.31M | -18.94M | -20.68M | -27.55M | -84.03M | -59.00M | -84.53M | -91.91M | -121.86M |
| Net Income | -20.24M | -19.17M | -18.75M | -26.51M | -84.69M | -58.03M | -81.17M | -83.58M | -117.26M |
| Diluted EPS | - | - | - | - | - | -227.42 | -53.08 | -9.37 | -12.48 |
| R&D Expense | 11.97M | 11.88M | 18.78M | 37.41M | 60.92M | 42.20M | 57.25M | 63.64M | 65.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Nov 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 44.55M | 223.22M | 264.72M | 185.36M | 73.74M | - | 221.66M | 226.24M | 113.51M |
| Total Equity | -9.66M | -29.64M | -48.28M | 167.36M | 192.49M | -42.21M | -99.03M | - | 169.91M | 160.41M | 51.44M |
| Cash & Equivalents | - | - | 42.19M | 200.16M | 220.34M | 79.64M | 36.33M | 36.60M | 166.15M | 55.64M | 21.82M |
| Long Term Debt | - | - | 349.00K | 180.00K | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 4.12M | 55.86M | 72.23M | 54.53M | 8.91M | - | 51.75M | 65.83M | 62.07M |
| Current Liabilities | - | - | 3.77M | 52.78M | 26.63M | 11.43M | 8.70M | - | 19.48M | 14.96M | 11.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.61M | -17.02M | 34.22M | -45.19M | -76.06M | -53.65M | -67.28M | -60.07M | -78.56M |
| Investing Cash Flow | -1.86M | -436.00K | -18.26M | 10.40M | -66.13M | 11.06M | 11.16M | -123.35M | 43.99M |
| Financing Cash Flow | 27.98M | 41.71M | 142.01M | 56.69M | 1.36M | 18.00K | 187.76M | 69.36M | 685.00K |
| Capital Expenditure | -1.86M | -436.00K | -1.06M | -6.67M | -2.91M | -5.14M | -7.84M | -17.90M | -518.00K |
| Free Cash Flow | -16.48M | -17.46M | 33.15M | -51.86M | -78.97M | -58.78M | -75.12M | -77.98M | -79.08M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -71.4% | -74.5% | -597.3% | - | - | -4,047.1% | -1,906.4% |
| Net Margin % | - | - | -64.8% | -71.7% | -602.0% | - | - | -3,680.4% | -1,834.5% |
| ROE % | 68.3% | 39.7% | -11.2% | -13.8% | 200.6% | 58.6% | -47.8% | -52.1% | -228.0% |
| ROCE % | - | -46.5% | -12.1% | -11.6% | -48.3% | -90.7% | -41.8% | -43.5% | -120.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management Lp | 10.45% | 1.54M | $15.63M |
| 2 | NEA Management Company, LLC | 8.81% | 1.30M | $13.19M |
| 3 | Venrock Adviser, LLC | 6.86% | 1.01M | $10.26M |
| 4 | Atlas Venture Life Science Advisors, LLC | 6.54% | 962.88K | $9.78M |
| 5 | Balyasny Asset Management LP | 6.46% | 951.78K | $9.67M |
| 6 | Blackrock Inc. | 5.55% | 817.62K | $8.31M |
| 7 | Affinity Asset Advisors, Llc | 4.80% | 706.90K | $7.18M |
| 8 | Nantahala Capital Management, LLC | 4.48% | 660.04K | $6.71M |
| 9 | Adage Capital Partners GP L.L.C. | 3.67% | 540.97K | $5.50M |
| 10 | Adar1 Capital Management, LLC | 3.67% | 540.05K | $5.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRRO
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNT2IzSVkzVGtsZjRKTkU3QUE4SkdLcWp0Vk9xbkN2SVc0aFFRNlcySmQtN09oZ0stZ3pQYTVmaTVDcTZhVWhwRGI0UXdGNzYwX0JKVnVYM0ozWGVXQ2lweGFyWUp0SVpFbXV3VGhlS3M2SHMxLVh3aWZLSlJ6dDkweUhQamdIRUY1RVg0N1…
Korro Bio(KRRO) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMilwNBVV95cUxQdkNBSnhzVHVtam9DM0hhdU5pSGhGQ09HOE10dGhRcGxXbDZZWWF5amtwUW11X0hILVJEbGVNXzVYREI4SzJMbVNrSVRjdVRZSVFPSzQ4SG5hM1FPUFNyQTdvME0wVDJkdUszeHFMZEdlSVhIcnBpZno4VmtKdmQ1QzNfZkIyc0d4OUhFRF…
KRRO Nov 2026 22.500 call (KRRO261120C00022500) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE95ZTVjUnZpYXVET2JnNDNwZGNZTDBkdXZNTU1ueThpWmFjb3lVSHplNHdVUHN6WUI1OWwxMW1sUXZIM2JMcVRoYUdyT3J5TnJhZmd2dDhyYkhtSi1NOHZ5b1FHcnU4dDk1VUtzREV3?oc=5" target="_blank">KRRO Nov 2026 22.50…
Korro Bio reports preclinical data for AATD treatment KRRO-111 By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPaDBWLUxhZXVteFZfemJQSFhUTlpORVEzV0VuQjhfMl9uT19HQTdsZ3FHWjFKUTUyMkxtM2I3Q0NXbVFOeHZsSVFxaGZGZjRnc2ppZGVEVVpWQ3ZlbHVWeml2ZWp5X0FLYzJadWF0YlJmdWVSbmk5UkRmMFNsZ2Rob0hSN3d5YXBnN1huR0…
Two new hires can earn the right to buy Korro Bio shares over four years. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb0g2TkxqUnNNSFdfWlBnZFNNOTdXVGpoSlVoZUpXa2xTOGItZ1RDeWtCdTUwTHYyV2Z6XzloX1U4bjFXTXBIMjRnNzhFWWFTQnpKTldMcFJaVEZWQXlySnUxVXN0aHEtRUJtWDZnVmtXcXVYWklWMzZhS2prbWkxRzVaZ0wxR004TmNFZH…
KRRO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBnR01VbXN6WHVaa0t6dmpCeFFteXBiY0Z0S2dMMEU1cVpCbmRzZFhBaDhxb1ZLZGNiNVNiWFotN3pyakJUSUlaTnI0V3Z3ZlRTdFRkMXJma1RSUEM2WWhDV25iLTROSnlFNko3dTJnMnhCaGFJU21rTHd3?oc=5" target="_blank">KRR…
KRRO — Frequently Asked Questions
What is the current share price of Korro Bio, Inc. (KRRO)?
As of 2026-10-23 16:27 PDT, Korro Bio, Inc. (KRRO) trades at $11.98 on NasdaqCM. Its 52-week range is $5.28 to $51.36.
What is the market capitalisation of KRRO?
Korro Bio, Inc. (KRRO) has a market capitalisation of $176.41M on NasdaqCM.
What is the P/E ratio of KRRO?
KRRO trades at a trailing price-to-earnings (P/E) ratio of -1.21. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.43.
What is the return on equity (ROE) of KRRO?
KRRO has a return on equity (ROE) of -97.69%. Its return on capital employed (ROCE) is -119.97%.
Is KRRO a good stock to buy?
This page provides a data-driven analysis of Korro Bio, Inc. (KRRO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.